The exact etiology of sporadic Alzheimer disease (AD) is unclear, but it is interesting that several cardiovascular risk factors are associated with higher incidence of AD. The link between these risk factors and AD has yet to be identified; however, a common feature is endothelial dysfunction, specifically, decreased bioavailability of nitric oxide (NO).
A lzheimer's disease (AD) is a chronic neurodegenerative disease affecting more than 5 million persons in the United States and more than 20 million worldwide. 1 AD is characterized by progressive loss of neurons, cognitive decline, and 2 defining histopathologies: extracellular amyloid plaques and intracellular tangles composed primarily of amyloid ␤ (A␤) peptide and hyperphosphorylated tau, respectively. 2 Furthermore, AD is often accompanied by cerebrovascular dysfunction, as well as amyloid deposition within the cerebral vessels, termed cerebral amyloid angiopathy. 3 A␤ is generated from sequential cleavages of its parent molecule, the amyloid precursor protein (APP), by the activities of ␤-site APP-cleaving enzyme (BACE)1 and ␥ secretase. 4, 5 Importantly, A␤ has been shown to exert a plethora of effects on endothelial phenotype, including angiogenesis, proliferation, adhesion, and responsiveness to vasoactive molecules. 6, 7 Moreover, it has been suggested that APP has functional roles in coagulation, adhesion, and inflammation. 8 The exact etiology of sporadic AD is unclear, but it is interesting that cardiovascular risk factors including hypertension, hypercholesterolemia, diabetes mellitus, aging, and sedentary lifestyle are associated with higher incidence of AD. 9 The link between cardiovascular risk factors and AD has yet to be identified; however, a common feature is endothelial dysfunction, specifically, decreased bioavailability of nitric oxide (NO). 10 In the cerebral circulation, endothelial NO is generated by endothelial nitric oxide synthase (eNOS), which, under basal conditions, is expressed exclusively in endothelial cells. 11 NO is an extremely important signaling molecule responsible for maintaining vascular homeostasis by promoting vasodilatation, inhibiting platelet aggregation and leukocyte adhesion. 12 Taken together, these data suggest that NO availability may be a common link between cardiovascular risk factors and the development of AD; therefore, we examine here the role of endothelial-derived NO in modulating brain and microvascular APP expression and processing and generation of the amyloidogenic fragment A␤.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org and includes detailed information regarding animals, tissue collection, cerebral microvessel isolation, human brain microvascular endothelial cell (BMEC) culture, confocal microscopy, eNOS, guanylyl cyclase and phosphodiesterase 5 inhibition, small interfering RNA transfection, Western blotting, ELISA for A␤, NOx measurements, BACE1 enzyme activity assay, and statistical analysis.
Results

eNOS-Derived NO and APP Expression and Processing in Human BMECs
Inhibition of eNOS led to increased APP and BACE1 protein levels after 3 days of treatment in BMECs ( Figure 1A and 1B). Addition of L-arginine, the stereoisomer-specific substrate of eNOS, was able to reverse the L-NAME-induced increases in APP and BACE1 protein levels ( Figure 1B) . Furthermore, genetic knockdown of eNOS led to similar increases in APP and BACE1 protein levels ( Figure 1D ). Levels of the amyloidogenic peptide A␤ were significantly higher following eNOS inhibition and attenuated with the addition of L-arginine ( Figure 1C ; PϽ0.001 from control).
cGMP Pathway and APP Expression and Processing
The effects of NO are commonly mediated by activation of guanylyl cyclase, which then generates cGMP. 13 BMECs treated with 1H- [1, 2, 4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ), a highly selective inhibitor of soluble guanylyl cyclase, had statistically higher protein levels of APP and BACE1 (Figure 2A ). Furthermore, when we treated BMECs with sildenafil, a selective inhibitor of cGMP-specific phosphodiesterase type 5, to increase cGMP levels, APP and BACE1 protein levels were significantly reduced ( Figure 2B ). Taken together, these data suggest that basal NO levels, provided by the activity of eNOS, suppress APP and BACE1 protein levels via the guanylyl cyclase pathway. 3 mmol/L L-NAME for 4 days; medium was changed daily. B, Representative image from 3 to 5 independent experiments and densitometric analysis are shown. Data are presented as meansϮSD. *PϽ0.05 from control; &PϽ0.05 from L-NAME; $PϽ0.01 from L-NAME. C, Cell supernatant was collected and secreted A␤ and A␤ was measured using a commercially available colorimetric ELISA. Data are represented as meansϮSD. ***PϽ0.001 from control; #PϽ0.001 from L-NAME; $PϽ0.01 from L-NAME; &PϽ0.05 from L-NAME. D, BMECs were transfected with 30 nmol/L eNOS or control small interfering RNA (siRNA). Cells were lysed 3 days after transfections and used for Western analyses. Representative image from 3 to 5 independent experiments and densitometric analysis are shown. Data are presented as meansϮSD. *PϽ0.05 from untreated; &PϽ0.05 from control siRNA. Statistical analysis was performed using 1-way ANOVA and Tukey-Kramer post hoc comparison. Microvessels from eNOS Ϫ/Ϫ mice displayed an approximately 50% reduction in the levels of nitrate/nitrite (NOx) as compared with wild-type controls ( Figure 3A ). Whereas overall NOx levels were decreased in the microvessels of eNOS Ϫ/Ϫ mice, protein expression of inducible (i)NOS were unchanged and neuronal (n)NOS was undetectable in the microvessels from both mice ( Figure 3B ).
Non-standard Abbreviations and Acronyms
APP and BACE1 protein levels from the microvascular fraction of both wild-type and eNOS Ϫ/Ϫ animals were studied. Whereas APP protein levels were not significantly different between the mice, BACE1 levels were statistically higher in the microvascular fraction from the eNOS Ϫ/Ϫ animals as compared with wild type ( Figure 3C ). Because the majority of A␤ produced by the endothelial cells would have been secreted into the vessel lumen, we were unable to detect A␤ levels from the microvascular fraction.
We did not detect any alterations in other key enzymes involved in APP processing or A␤ degradation (Online Figures I and II) . 14 
APP, BACE1, and A␤ in the Brains of eNOS
؊/؊ Mice Levels of brain NOx were unchanged between eNOS Ϫ/Ϫ and wild-type control mice ( Figure 4A ). Furthermore, protein levels of iNOS and nNOS were unaltered in the brains of eNOS Ϫ/Ϫ mice as compared with wild-type control ( Figure  2B and 2C) . These results suggest that the deficiency in eNOS-derived NO is restricted to the microvessels.
APP and BACE1 protein levels were significantly higher in the brains of eNOS Ϫ/Ϫ animals as compared with control ( Figure 4D and 4E) . Levels of active BACE1 enzyme were also Ϫ/Ϫ and wild-type animals was collected and analyzed for levels of NOx using a commercially available kit. Data are presented as mean NOx levels expressed in pmol/g brain tissue (6 to 8 animals per background; *PϽ0.05 from wild-type control). B and C, Brain microvascular tissue from eNOS Ϫ/Ϫ and wild-type control animals was Western blotted using anti-eNOS, anti-iNOS, anti-nNOS, and anti-actin (loading control) antibodies (B) or anti-APP, anti-BACE1, anti-eNOS, and antiactin (loading control) antibodies (C). Representative Western blot and densitometric analysis are shown (6 to 8 animals). Data are presented as relative mean optical density (O.D.)ϮSD. *PϽ0.05, ***PϽ0.001 from wild-type control.
statistically higher in the brains of eNOS Ϫ/Ϫ animals as compared with wild-type control mice ( Figure 4F ; PϽ0.001). Furthermore, brain lysates from eNOS Ϫ/Ϫ animals demonstrated significantly higher levels of both A␤ 1-40 and A␤ 1-42 as compared with wild type (Figure 4G and 4H ; PϽ0.01, PϽ0.05, respectively). Importantly, this demonstrates that loss of endothelial NO is sufficient to increase protein levels of APP, BACE1, and the amyloidogenic A␤ peptide in brain tissue.
We observed no alteration in the ␣ or ␥ secretase proteins or A␤ degradation enzymes (Online Figures III and IV) .
Discussion
Our results support the concept that the relationship between endothelial dysfunction and the development of AD is at least in part mediated by the loss of basal eNOS-generated NO and subsequent upregulation of expression and amyloidogenic processing of APP. We have observed this both in vitro and in vivo. Our in vitro data suggest that this NO-dependent mechanism is mediated by activation of guanylyl cyclase, leading to increases in cGMP levels, because inhibition of guanylyl cyclase also led to increases in APP and BACE1 protein expression, whereas phosphodiesterase type 5 lowered APP and BACE1 expression. Consistent with our observations, Pak et al 15 demonstrated that in human neuroblastoma cells, NO downregulated ␤ secretase, suggesting that NO might suppress A␤ levels in the brain. Our in vivo observations demonstrate that endothelial-derived NO modulates APP and BACE1 expression, not only within the vessels themselves, but also in brain tissue. Most importantly, endothelial NO also seems to inhibit A␤ generation and secretion. Our findings also suggest that the effect of NO is selective for BACE1 because we did not detect alterations in expression of ␣-secretases, ␥-secretases, or A␤ degradation enzymes.
It is important to note that, phenotypically, eNOS Ϫ/Ϫ animals have a higher resting mean arterial blood pressure and are prone to insulin resistance as compared with wild-type animals. 16 Although additional studies are required to determine the exact contribution of hypertension and insulin resistance to the elevation of A␤, our in vitro data indicate that loss of endothelial NO is sufficient to increase APP, BACE1, and A␤ levels in the absence of any hemodynamic forces or insulin resistance. In addition, existing evidence suggests that hypoperfusion can lead to alterations in brain APP and A␤ levels; however, prior reports demonstrated that cerebral blood flow is normal in eNOS Ϫ/Ϫ animals. 17, 18 The results from the present study demonstrate that the NO/cGMP pathway plays an important role in maintaining APP, BACE1, and A␤ levels within the brain and cerebral microvasculature and that this may provide a therapeutic target in treating and preventing mild cognitive impairment, as well as AD. Indeed, in humans, physical exercise has been shown to be protective against developing AD. 19 Moreover, elevated shear stress imposed on the endothelium by exercise-induced increased blood flow is known to upregulate eNOS. 20 Taken together, our findings offer novel insights into previously unrecognized mechanisms underlying the beneficial effects of eNOS-derived NO on prevention of A␤ elevation in cerebrovascular and neuronal tissue. 
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Novelty and Significance
What Is Known?
• Amyloid precursor protein (APP) is the parent molecule that when sequentially cleaved by ␤-site APP cleaving enzyme 1 (BACE1) and ␥-secretase generates the amyloid ␤ (A␤) peptide which is the primary component of Alzheimer's disease (AD) plaques.
• Cardiovascular risk factors such as hypertension, hypercholsterolemia, diabetes mellitus, aging and a sedentary lifestyle are associated with a higher incidence of AD.
• Endothelial dysfunction caused by decreased bioavailability of nitric oxide (NO) is a common feature among cardiovascular risk factors.
What New Information Does This Article Contribute?
• Endothelial-derived NO suppresses APP, BACE1 and A␤ by increasing cyclic guanosine monophosphate (cGMP) in brain microvascular endothelial cells (BMECs).
• Endothelial nitric oxide synthase (eNOS) deficient (eNOS Ϫ/Ϫ ) mice display increased APP, BACE1, and A␤ peptide in brain tissue and increased BACE1 protein levels in the cerebral microvasculature when compared with wild-type control mice.
• NO-mediated effects were specific to APP and BACE1 as there were no differences in the other secretase enzymes or A␤-degradation enzymes between eNOS Ϫ/Ϫ and wild-type l mice.
Several cardiovascular risk factors are associated with a higher incidence of AD. We show for the first time that loss of endothelial derived NO generated by eNOS leads to an increase in APP, BACE1 and A␤ peptide both in cultured BMECs and in the brains of eNOS Ϫ/Ϫ mice. Our data suggest that endothelial NO plays an important role in suppressing APP, BACE1 and A␤ levels within the brain and cerebral vasculature. These findings identify a previously unrecognized mechanism linking endothelial dysfunction with amyloidogenic processing of APP. Our results suggest that preservation of the NO/cGMP signaling pathway may be an important therapeutic strategy for preventing and treating mild cognitive impairment as well as AD.
